FEDERAL COURT OF AUSTRALIA
Novartis AG v Pharmacor Pty Limited (No 3) [2024] FCA 1307
File number: NSD 506 of 2023 Judgment of: YATES J Date of judgment: 13 November 2024 Catchwords: PATENTS – infringement – standard patent for a pharmaceutical composition containing certain active pharmaceutical ingredients (APIs) – claim construction – whether claim covers a pharmaceutical composition where the API is in the form of a complex in which the ions are associated by non-covalent bonds
PATENTS – identity of the person skilled in the art – where the person skilled in the art is understood as a “team” – discussion of the characteristics of the person skilled in the art
PATENTS – validity – lack of inventive step – availability of prior art information – whether person skilled in the art could be reasonably expected to have ascertained and regarded as relevant certain prior art publications
PATENTS – validity – lack of inventive step – discussion of the reformulated “Cripps question” – whether obviousness established on the evidence
PATENTS – extension of patent term – whether extension validly granted – whether rectification of the Register of Patents should be ordered
PATENTS – The Last Judgment
Legislation: Patents Act 1990 (Cth) ss 7, 18, 40, 70, 138, 192 Cases cited: Aktiebolaget Hassle v Alphapharm Pty Limited [2002] HCA 59; 212 CLR 411
Application of Tomlinson (1966) 363 F 2d 928
Aspirating IP Limited v Vision Systems Limited [2010] FCA 1061; 88 IPR 52
AstraZeneca AB v Apotex Pty Ltd [2014] FCAFC 99; 226 FCR 324
AstraZeneca AB v Apotex Pty Ltd [2015] HCA 30; 257 CLR 356
Boehringer Ingelheim Animal Health USA Inc v Intervet International BV [2022] FCAFC 88; 166 IPR 468
Catnic Components v Hill & Smith Ltd [1982] RPC 183
Commissioner of Patents v Ono Pharmaceutical Co. Ltd [2022] FCAFC 39; 291 FCR 1
Crane v Price (1842) 4 Man & G 580
Dow Corning Corporation’s Application [1969] RPC 544
Federal Commissioner of Taxation v Peabody [1994] HCA 43; 181 CLR 359
General Tire & Rubber Co v Firestone Tyre & Rubber Co Ltd [1972] RPC 457
Generic Health Pty Ltd v Bayer Pharma Aktiengesellschaft [2014] FCAFC 73; 222 FCR 336
GlaxoSmithKline Consumer Healthcare Investments (Ireland) (No 2) Ltd v Generic Partners Pty Ltd [2018] FCAFC 71; 264 FCR 474
H Lundbeck A/S v Alphapharm Pty Ltd [2009] FCAFC 70; 177 FCR 151
Hanwha Solutions Corporation v REC Solar Pte Ltd [2023] FCA 1017
Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 9
Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (No 2) [2007] HCA 21; 235 CLR 173
MMD Australia Pty Ltd v Camco Engineering Pty Ltd [2024] FCAFC 38
Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd [2020] FCAFC 116; 279 FRC 354
Novartis AG v Pharmacor Pty Limited [2023] FCA 804
Olin Mathieson Chemical Corporation v Biorex Laboratories Ltd [1970] RPC 157
Keep reading for free
Create a free CaseChat account to read Novartis AG v Pharmacor Pty Limited (No 3) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2024] FCA 1307
- Decision Date
CaseChat Overview and Summary
The legal issues encompassed the proper construction of the patent claims, particularly whether they extended to pharmaceutical compositions where the active pharmaceutical ingredients were in the form of a complex with ions associated by non-covalent bonds. The court also had to identify the relevant person skilled in the art, considering whether this person should be viewed as an individual or a team, and evaluate whether the skilled person could reasonably have identified and considered relevant prior art. The court further needed to decide if the invention lacked an inventive step and if the patent term extension was validly granted, warranting rectification of the Register of Patents.
In its reasoning, the court determined that the claims were properly construed and did not cover the specific pharmaceutical compositions at issue. The court held that the person skilled in the art should be understood as a team, incorporating collective knowledge and expertise. It found that the prior art was not sufficiently identified and considered by the skilled person, which did not establish a lack of inventive step. The court also concluded that the patent term extension was validly granted, and there was no basis for rectifying the Register of Patents. Consequently, the patent was found to be valid, and no infringement occurred.
The final orders required the parties to submit agreed or competing draft orders by a specified deadline to implement the court's decision.
Orders
Orders of the court
1. The parties bring in agreed or, if not agreed competing, draft orders giving effect to these reasons by no later than 4.00pm on 20 November 2024.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi